fig5
Figure 5. US-based evaluation of PTX-based therapeutic effect. (A) Distribution of patients according to size of residual tumor after two cycles of PTX; and (B) correlation between residual tumor size and Ki-67 expression in specimens from diagnostic biopsy. Both graphs were plotted using GraphPad Prism software. PTX: Paclitaxel.
